familial Mediterranean fever

Summary

familial Mediterranean fever (MONDO:0018088) is a disease caused by MEFV (GenCC Definitive), with 1 cohort gene and 59 clinical trials. Top therapeutic interventions include colchicine, anakinra, and rilonacept.

At a glance

• Prevalence: >1 / 1000 (Armenia) [Orphanet-validated]
• Causal gene: MEFV (GenCC Definitive)
• Cohort genes: 1
• ClinVar variants: 1,189
• Phenotypes (HPO): 50
• Clinical trials: 59

Clinical features

Epidemiology

Prevalence records

6 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	>1 / 1000	200	Armenia	Validated
Point prevalence	1-9 / 100 000	2.5	Sweden	Validated
Point prevalence	1-5 / 10 000		Europe	Not yet validated
Annual incidence	1-5 / 10 000	14	Specific population	Not yet validated
Point prevalence	>1 / 1000	175	Turkey	Not yet validated
Point prevalence	1-9 / 1 000 000	0.23	Japan	Not yet validated

Signs & symptoms

Clinical features (HPO)

50 HPO clinical features (Orphanet curated; top 50 by frequency):

HPO ID	Term	Frequency
HP:0002019	Constipation	Very frequent (80-99%)
HP:0002027	Abdominal pain	Very frequent (80-99%)
HP:0002829	Arthralgia	Very frequent (80-99%)
HP:0003326	Myalgia	Very frequent (80-99%)
HP:0001945	Fever	Very frequent (80-99%)
HP:0002017	Nausea and vomiting	Very frequent (80-99%)
HP:0000093	Proteinuria	Frequent (30-79%)
HP:0000737	Irritability	Frequent (30-79%)
HP:0001055	Erysipelas	Frequent (30-79%)
HP:0001250	Seizure	Frequent (30-79%)
HP:0001369	Arthritis	Frequent (30-79%)
HP:0001974	Leukocytosis	Frequent (30-79%)
HP:0002014	Diarrhea	Frequent (30-79%)
HP:0002102	Pleuritis	Frequent (30-79%)
HP:0002360	Sleep abnormality	Frequent (30-79%)
HP:0002745	Oral leukoplakia	Frequent (30-79%)
HP:0004396	Poor appetite	Frequent (30-79%)
HP:0005764	Polyarticular arthritis	Frequent (30-79%)
HP:0010783	Erythema	Frequent (30-79%)
HP:0011899	Hyperfibrinogenemia	Frequent (30-79%)
HP:0012378	Fatigue	Frequent (30-79%)
HP:0025406	Asthenia	Frequent (30-79%)
HP:0033748	Hypoesthesia	Frequent (30-79%)
HP:0100749	Chest pain	Frequent (30-79%)
HP:0000100	Nephrotic syndrome	Occasional (5-29%)
HP:0000112	Nephropathy	Occasional (5-29%)
HP:0000121	Nephrocalcinosis	Occasional (5-29%)
HP:0000716	Depression	Occasional (5-29%)
HP:0000739	Anxiety	Occasional (5-29%)
HP:0000988	Skin rash	Occasional (5-29%)
HP:0001287	Meningitis	Occasional (5-29%)
HP:0001541	Ascites	Occasional (5-29%)
HP:0001658	Myocardial infarction	Occasional (5-29%)
HP:0001733	Pancreatitis	Occasional (5-29%)
HP:0001744	Splenomegaly	Occasional (5-29%)
HP:0002024	Malabsorption	Occasional (5-29%)
HP:0002586	Peritonitis	Occasional (5-29%)
HP:0002633	Vasculitis	Occasional (5-29%)
HP:0002716	Lymphadenopathy	Occasional (5-29%)
HP:0002758	Osteoarthritis	Occasional (5-29%)
HP:0003419	Low back pain	Occasional (5-29%)
HP:0003565	Elevated erythrocyte sedimentation rate	Occasional (5-29%)
HP:0005214	Intestinal obstruction	Occasional (5-29%)
HP:0005244	Gastrointestinal infarctions	Occasional (5-29%)
HP:0006554	Acute hepatic failure	Occasional (5-29%)
HP:0010741	Pedal edema	Occasional (5-29%)
HP:0011034	Amyloidosis	Occasional (5-29%)
HP:0011675	Arrhythmia	Occasional (5-29%)
HP:0100796	Orchitis	Occasional (5-29%)
HP:0001701	Pericarditis	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	familial Mediterranean fever
Mondo ID	MONDO:0018088
MeSH	D010505
Orphanet	342
DOID	DOID:2987
ICD-11	1373335705
NCIT	C84707
SNOMED CT	12579009
UMLS	C0031069
MedGen	45811
GARD	0006421
MedDRA	10016207
NORD	1130
Is cancer (heuristic)	no

Also known as: benign paroxysmal peritonitis · benign recurrent polyserositis · familial paroxysmal polyserositis · Fiebre mediterránea familiar · FMF · periodic disease

Data availability: 1,189 ClinVar variants · 3 GenCC gene-disease records · 9 cell lines.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › immune system disorder › familial Mediterranean fever

Related subtypes (46): hypersensitivity reaction disease, immune system cancer, immune system organ benign neoplasm, bone marrow disorder, thymus gland disorder, inborn error of immunity, leukocyte disorder, psoriasis, spondyloarthropathy, aggressive insulitis, benign insulitis, inflammatory bowel disease, autoimmune disease, TNF receptor 1-associated periodic fever syndrome, epidermodysplasia verruciformis, Vici syndrome, proteosome-associated autoinflammatory syndrome, hyperimmunoglobulinemia D with periodic fever, transcobalamin II deficiency, pyogenic arthritis-pyoderma gangrenosum-acne syndrome, granulomatosis with polyangiitis, autosomal recessive osteopetrosis 7, graft versus host disease, congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome, Roifman syndrome, cryopyrin-associated periodic syndrome, anti-HLA hyperimmunization, acquired immunodeficiency, erythroderma desquamativum, autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis, 22q11.2 deletion syndrome, T-cell large granular lymphocyte leukemia, twin to twin transfusion syndrome, immunodeficiency disease, immunoproliferative disorder, cytokine receptor deficiency, immunodeficiency-related disorder, phagocytic cell dysfunction, thrombocytopenic purpura, lymphoid system disorder, immune reconstitution inflammatory syndrome, growth hormone insensitivity with immune dysregulation 1, autosomal recessive, cytokine release syndrome, early-onset autoimmunity-autoinflammation-immunodeficiency syndrome, CADINS disease, autoinflammation, panniculitis, and dermatosis syndrome

Subtypes (2): familial Mediterranean fever, autosomal dominant, autosomal recessive familial Mediterranean fever

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

600 retrieved; paginated sample, class counts are floors:

319 likely benign, 174 uncertain significance, 82 conflicting classifications of pathogenicity, 7 benign/likely benign, 6 pathogenic/likely pathogenic, 4 benign, 3 pathogenic, 3 not provided, 2 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
1802172	NM_000243.3(MEFV):c.[2080A>G];[2177T>C]		Pathogenic	criteria provided, single submitter
234365	NM_000243.3(MEFV):c.2040G>T (p.Met680Ile)	LOC126862264	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2538	NM_000243.3(MEFV):c.2080A>G (p.Met694Val)	LOC126862264	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2539	NM_000243.3(MEFV):c.2082G>A (p.Met694Ile)	LOC126862264	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2550	NM_000243.3(MEFV):c.2040G>A (p.Met680Ile)	LOC126862264	Pathogenic	criteria provided, multiple submitters, no conflicts
2553	NM_000243.3(MEFV):c.1958G>A (p.Arg653His)	LOC126862264	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1179060	NM_000243.3(MEFV):c.1510C>T (p.Gln504Ter)	MEFV	Pathogenic	criteria provided, single submitter
2540	NM_000243.3(MEFV):c.2177T>C (p.Val726Ala)	MEFV	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2549	NM_000243.3(MEFV):c.2282G>A (p.Arg761His)	MEFV	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1179055	NM_000243.3(MEFV):c.1597_1598dup (p.Asp533fs)	MEFV	Likely pathogenic	criteria provided, single submitter
1677080	NM_000243.3(MEFV):c.1506_1507dup (p.Ser503fs)	MEFV	Likely pathogenic	criteria provided, single submitter
1062670	NM_000243.3(MEFV):c.1957C>A (p.Arg653Ser)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1321418	NM_000243.3(MEFV):c.1793-19A>G	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1467370	NM_000243.3(MEFV):c.1685A>G (p.Gln562Arg)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1478684	NM_000243.3(MEFV):c.2078T>C (p.Met693Thr)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1650419	NM_000243.3(MEFV):c.1782G>A (p.Gln594=)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
234363	NM_000243.3(MEFV):c.1759+1G>A	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
234364	NM_000243.3(MEFV):c.1886dup (p.Pro630fs)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
234366	NM_000243.3(MEFV):c.2146A>G (p.Lys716Glu)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
234551	NM_000243.3(MEFV):c.2141C>T (p.Pro714Leu)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2547	NM_000243.3(MEFV):c.2084A>G (p.Lys695Arg)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2556	NM_000243.3(MEFV):c.2078TGA[1] (p.Met694del)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
289866	NM_000243.3(MEFV):c.1957C>T (p.Arg653Cys)	LOC126862264	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1006519	NM_000243.3(MEFV):c.520A>G (p.Lys174Glu)	MEFV	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1009611	NM_000243.3(MEFV):c.319T>G (p.Ser107Ala)	MEFV	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1011684	NM_000243.3(MEFV):c.475A>G (p.Ser159Gly)	MEFV	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1012389	NM_000243.3(MEFV):c.199G>A (p.Val67Met)	MEFV	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1018295	NM_000243.3(MEFV):c.2310_2313del (p.Thr771fs)	MEFV	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1036172	NM_000243.3(MEFV):c.839G>A (p.Arg280Lys)	MEFV	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1036920	NM_000243.3(MEFV):c.201_202delinsTT (p.Gln68Ter)	MEFV	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 5 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
MEFV	Definitive	Autosomal recessive	familial Mediterranean fever	5

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MEFV	Orphanet:117	Behçet disease
MEFV	Orphanet:3243	Sweet syndrome
MEFV	Orphanet:329967	Intermittent hydrarthrosis
MEFV	Orphanet:342	Familial Mediterranean fever

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
MEFV	HGNC:6998	ENSG00000103313	O15553	Pyrin	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
MEFV	Pyrin	Involved in the regulation of innate immunity and the inflammatory response in response to IFNG/IFN-gamma.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	8.3×	0.121

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
MEFV	Transcription factor	no		Znf_B-box, B30.2/SPRY, SPRY_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
buccal mucosa cell	1
monocyte	1
mononuclear cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
MEFV	153	broad	marker	buccal mucosa cell, monocyte, mononuclear cell

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MEFV	2,217

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MEFV	O15553	11

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 11. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Inflammasomes	1	1142.0×	0.005	MEFV
Cell recruitment (pro-inflammatory response)	1	1142.0×	0.005	MEFV
The NLRP3 inflammasome	1	671.8×	0.005	MEFV
Purinergic signaling in leishmaniasis infection	1	423.0×	0.006	MEFV
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	1	356.9×	0.006	MEFV
Leishmania infection	1	163.1×	0.010	MEFV
Parasitic Infection Pathways	1	163.1×	0.010	MEFV
Innate Immune System	1	25.5×	0.049	MEFV
Infectious disease	1	24.8×	0.049	MEFV
Disease	1	13.1×	0.077	MEFV
Immune System	1	13.0×	0.077	MEFV

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
pyroptosome complex assembly	1	8426.0×	0.002	MEFV
negative regulation of macrophage inflammatory protein 1 alpha production	1	5617.3×	0.002	MEFV
regulation of interleukin-1 beta production	1	2106.5×	0.003	MEFV
negative regulation of interleukin-12 production	1	1053.2×	0.003	MEFV
pattern recognition receptor signaling pathway	1	991.3×	0.003	MEFV
negative regulation of NLRP3 inflammasome complex assembly	1	991.3×	0.003	MEFV
response to type II interferon	1	526.6×	0.004	MEFV
negative regulation of interleukin-1 beta production	1	510.7×	0.004	MEFV
pyroptotic inflammatory response	1	510.7×	0.004	MEFV
negative regulation of cytokine production involved in inflammatory response	1	421.3×	0.004	MEFV
positive regulation of interleukin-1 beta production	1	259.3×	0.006	MEFV
positive regulation of autophagy	1	208.1×	0.007	MEFV
positive regulation of inflammatory response	1	145.3×	0.009	MEFV
negative regulation of inflammatory response	1	137.0×	0.009	MEFV
regulation of gene expression	1	83.4×	0.014	MEFV
inflammatory response	1	37.7×	0.028	MEFV
innate immune response	1	33.6×	0.030	MEFV

Therapeutics

Drugs indicated for this disease

2 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Canakinumab	Approved (phase 4)
Colchicine	Approved (phase 4)
Anakinra	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Goflikicept, Rilonacept, Sodium Chloride, Tocilizumab.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MEFV	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MEFV	1	Binding:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	MEFV

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
MEFV	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 59.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	46
PHASE2	8
PHASE4	2
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06666335	PHASE4	NOT_YET_RECRUITING	A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
NCT02602028	PHASE4	COMPLETED	The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF
NCT06336733	PHASE3	RECRUITING	Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
NCT01705756	PHASE3	COMPLETED	Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever
NCT05092776	PHASE2	ACTIVE_NOT_RECRUITING	Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
NCT05190991	PHASE2	RECRUITING	Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
NCT00094900	PHASE2	COMPLETED	Interleukin-1 Trap to Treat Autoinflammatory Diseases
NCT00582907	PHASE2	COMPLETED	Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
NCT01088880	PHASE2	COMPLETED	Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
NCT02175589	PHASE2	UNKNOWN	Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation
NCT03446209	PHASE2	COMPLETED	Tocilizumab for the Treatment of Familial Mediterranean Fever
NCT05448391	PHASE2	WITHDRAWN	A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)
NCT01075906	PHASE1	COMPLETED	Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients
NCT00001373	Not specified	RECRUITING	Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
NCT04478409	Not specified	RECRUITING	Characterization of a Functional Test for Mediterranean Family Fever Screening - 2
NCT05292768	Not specified	NOT_YET_RECRUITING	Are Mast Cells Involved in Autoinflammatory Diseases
NCT06257342	Not specified	ACTIVE_NOT_RECRUITING	Physical Abilities of Teenagers With Familial Mediterranean Fever
NCT06338891	Not specified	RECRUITING	Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks
NCT06583304	Not specified	NOT_YET_RECRUITING	Hematological Indices in Pediatric Diagnosed With Familial Mediterranean Fever
NCT06705673	Not specified	NOT_YET_RECRUITING	Gait Profile and Variables in Pediatric Rheumatic Disease Using a Smart Insole System
NCT06725849	Not specified	NOT_YET_RECRUITING	Barriers to Physical Activity in Familial Mediterranean Fever
NCT06743152	Not specified	NOT_YET_RECRUITING	Comparison of the Effects of Synchronous and Asynchronous Telerehabilitation in Patients with Juvenile Familial Mediterranean Fever
NCT06830213	Not specified	NOT_YET_RECRUITING	Investigation of the Validity, Reliability and Responsiveness of the BETY-BQ in FMF
NCT06974942	Not specified	NOT_YET_RECRUITING	Physical Activity in Adolescents With Familial Mediterranean Fever
NCT06981520	Not specified	NOT_YET_RECRUITING	Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF
NCT07013045	Not specified	ENROLLING_BY_INVITATION	Comparing Structured Neuromuscular Exercise and Exergaming Program in Adolescents With Familial Mediterranean Fever
NCT07077473	Not specified	RECRUITING	Observing the Efficacy and Safety of Different Drugs Used in Real-world Familial Mediterranean Fever (FMF) Cases
NCT07128225	Not specified	ACTIVE_NOT_RECRUITING	Health-related Quality of Life, Electrocardiographic and Holter Findings in Children With Familial Mediterranean Fever
NCT07129538	Not specified	RECRUITING	Outcomes of Inspiratory Muscle Training in FMF Adolescents
NCT07130305	Not specified	RECRUITING	is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever
NCT07130318	Not specified	RECRUITING	Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise
NCT07212764	Not specified	ENROLLING_BY_INVITATION	Mobile App-Based Infection Monitoring in Familial Mediterranean Fever
NCT07329556	Not specified	NOT_YET_RECRUITING	Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases
NCT07439341	Not specified	NOT_YET_RECRUITING	AGE and CALLY Index in Familial Mediterranean Fever
NCT07517250	Not specified	RECRUITING	A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still’s Disease Patients
NCT00323440	Not specified	WITHDRAWN	Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission
NCT00658060	Not specified	UNKNOWN	Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients
NCT01059279	Not specified	TERMINATED	Heat Intolerance in the Group of FMF Patients
NCT02021084	Not specified	WITHDRAWN	The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever.
NCT02466217	Not specified	COMPLETED	Phenomics in Autoimmune and Inflammatory Diseases

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
COLCHICINE	4	4
ANAKINRA	4	3
RILONACEPT	4	2
CANAKINUMAB	4	1
GOFLIKICEPT	3	2
VIMNERIXIN	2	1
CHEMBL5220618	0	2
CHEMBL2368770	0	1